Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
288.6 SEK | +1.48% | +5.79% | +8.09% |
Sales 2024 * | 24.57B 2.37B | Sales 2025 * | 27.25B 2.63B | Capitalization | 98.09B 9.46B |
---|---|---|---|---|---|
Net income 2024 * | 3.41B 329M | Net income 2025 * | 4.99B 481M | EV / Sales 2024 * | 4.58 x |
Net Debt 2024 * | 14.46B 1.39B | Net Debt 2025 * | 8.87B 855M | EV / Sales 2025 * | 3.93 x |
P/E ratio 2024 * |
28.9
x | P/E ratio 2025 * |
19.8
x | Employees | 1,752 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.9% |
Latest transcript on Swedish Orphan Biovitrum AB
1 day | +1.48% | ||
1 week | +5.79% | ||
Current month | +2.20% | ||
1 month | +3.07% | ||
3 months | +8.41% | ||
6 months | +14.80% | ||
Current year | +8.09% |
Managers | Title | Age | Since |
---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 59 | 17-05-21 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 57 | 18-07-19 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 20-12-31 | |
Annette Clancy
CHM | Chairman | 70 | 14-05-07 |
Staffan Schüberg
BRD | Director/Board Member | 55 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.15% | 232 M€ | +13.20% | ||
0.90% | 5 M€ | +17.05% | ||
0.69% | 142 M€ | +12.57% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 288.6 | +1.48% | 204,033 |
24-06-04 | 284.4 | +0.49% | 385,214 |
24-06-03 | 283 | +0.21% | 301,264 |
24-05-31 | 282.4 | +1.66% | 706,896 |
24-05-30 | 277.8 | +1.83% | 254,615 |
Delayed Quote Nasdaq Stockholm, June 05, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.09% | 9.41B | |
+1.25% | 91.72B | |
0.00% | 39.44B | |
-8.52% | 34.47B | |
+64.13% | 26.7B | |
-17.37% | 15.13B | |
-5.99% | 13.27B | |
-10.69% | 11.74B | |
-47.78% | 10.54B | |
+141.62% | 9.22B |
- Stock Market
- Equities
- SOBI Stock